Agree. Also that spin should have been reported if part of original agreement? Maybe that is what China wanted for approval of business requirement? If so disclosure required! The way China operates "loosey goosey".
Maybe part of China approval was some equity ownership? Sales maybe be fine tuning with what Chinese health authorities allow or require? Money better spent on Celution/procedures in China, as, returns will be better than owning CYTX. Some indicated he needed tax money?
I do not know how China looks at foreign investment. I was treasurer for a mutual fund complex and as a US fund Singapore and Thailand were a "bitXX" to comply with. That was 15 years ago so times may have changed.
In an article by Seeking Alpha, initial China approval would "In addition, Lorem Vascular will order $7 million in Celution® devices and consumables with a $2 million order placed immediately and a $5 million order to be placed following regulatory approval in China."
You are understanding provision incorrectly. Lorem is committed to purchase at a minimum 50 and 50. All this does is to pressure Lorem to advance partnerships with hospital, clinics within China, etc and not sit on the technology. If CYTX technology is pronounced effective sales of celution and consumables eill skyrocket.